Entero Therapeutics, Inc./$GRDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entero Therapeutics, Inc.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Ticker
$GRDX
Sector
Primary listing
Employees
2
Headquarters
Website
GRDX Metrics
BasicAdvanced
$7m
-
-$10.85
0.81
-
Price and volume
Market cap
$7m
Beta
0.81
52-week high
$5.84
52-week low
$1.65
Average daily volume
287k
Financial strength
Current ratio
2.808
Quick ratio
0
Total debt to equity
1.509
Interest coverage (TTM)
-84.43%
Profitability
EBITDA (TTM)
-4.582
Effective tax rate (TTM)
-225.04%
Management effectiveness
Return on assets (TTM)
-3.32%
Return on equity (TTM)
-24.28%
Valuation
Price to book
-1.12
Price to tangible book (TTM)
-0.88
Price to free cash flow (TTM)
-2.451
Free cash flow yield (TTM)
-40.79%
Free cash flow per share (TTM)
-1.807
Growth
Earnings per share change (TTM)
-57.85%
GRDX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs